Fast growth for recently label-expanded drugs fuelled Novartis’ Q3 performance, despite headwinds from generic competition.

Scientists uncover a molecular weakness that could transform prostate cancer therapy. An international team of researchers has identified a new weakness in prostate cancer cells that could enhance ...

Clarity Pharmaceuticals Ltd. (($AU:CU6)) announced an update on their ongoing clinical study. Clarity Pharmaceuticals Ltd. is conducting a Phase 3 ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

According to Precedence Research, the global kidney stone management market size will grow from USD 2.67 billion in 2025 to ...

Former President Joe Biden called these “dark days” as he urged Americans to stay optimistic and not to check out in response ...

A globally-renowned prostate cancer surgeon shares the latest advancements in the field and stresses the importance of early ...

The 2025 edition of the European Society for Medical Oncology(ESMO) was held this week in Berlin, delve into its key ...

Xie of Wanhuida Intellectual Property analyses how China’s patent authorities and courts assess second medical use inventions ...

The center will be located on the Penn Med Princeton Medical Center campus, marking the largest expansion of Princeton Health ...

Expedition Medicines has emerged from stealth with $50 million in funding from Flagship Pioneering. The start-up uses ...

Maxi Dottori, 31, took Duromine when she was 20 as a 'quick fix' to lose weight but didn't last longer than four weeks on the prescribed weight loss medication due to horrific side effects.